MONOSUBSTITUTED OR DISSUBSTITUTED INDOL DERIVATIVES USED AS DENGUE VIRUS REPLICATION INHIBITORS
Patent Information
- Application Number
- MA42811
- Authority / Receiving Office
- MA · MA
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2016-09-15
- Filing Date
- 2016-09-15
- Publication Date
- 2018-07-25
- Estimated Expiration
- 2036-09-15
AI Technical Summary
Current treatments for dengue virus infection lack effective inhibitors that can target and inhibit the replication of the virus, posing a challenge in managing the disease effectively.
Development of monosubstituted or disubstituted indole derivatives in stereoisomeric, pharmaceutically acceptable forms, including solvates or polymorphs, which act as inhibitors of dengue virus replication.
The developed indole derivatives effectively inhibit dengue virus replication, providing a promising therapeutic option for managing dengue infection.
Abstract
Description
KINGDOM OF MOROCCO Moroccan Property Tax INDUSTRIAL AND COMMERCIAL WIPO Demands طةئمقئج ؛ تبمكجارية 1. Formula compound (I) stereoisomeric form, pharmaceutically acceptable, solvate or polymorphic thereof comprising an indole group mono- or disubstituted said component being chosen from the group in which: R] is H, R^ is F or R] is F, R^ is F and Cl and Rs is H or CH R is H; R] is CH, R^ is CCH and Rs is H; R] is CH, R^ is F and Rs is H; R] is CH, R^ is H and Rs is F; R] is Cl, R^ is H and Rs is CH; R] is OCFs, R^ is H or CCH and Rs is H and R] is OCFs, R^ is H and Rs is CHs. 2. Compound or its stereoisomeric form, salt pharmaceutically acceptable, solvate or polymorph of that- according to claim 1, said compound being chosen from the group:
Claims
comprising a compound of stereoisomers, a solvate or a polymorph of or 2 jointly with a diluent or vehicle 3, Pharmaceutical composition formula (I) or a pharmaceutically acceptable form, one or more pharmaceutically acceptable excipients according to claim 1. WIPO 4. Compound of formula (I) or stereoisomeric form, pharmaceutically acceptable salt, solvate or polymorph thereof according to claim 1 or pharmaceutical composition according to claim 3 for use as a medicinal product.
5. Compound of formula (I) or stereoisomeric form, pharmaceutically acceptable salt, solvate or polymorph thereof according to claim 1 or pharmaceutical composition according to claim 3 for use in the treatment of dengue. structural formula (I) stereoisomeric form. pharmaceutically acceptable salt. solvate or polymorph of it comprising an indole group mono- or disubstituted; said compound being chosen from the group in which: Ri is H, R2 is F or Ri is F, Ra is F and Cl and Fs is H or CH R is H; Ri is CH, R is OCH and R3 is H; Ri is CH, R is F and R3 is H; Ri is CH, R2 is H and R3 is F; Ri is Cl, R2 is H and Ra is CH; Ri is 0CF3, Rs is H or 0CH3 and R3 is H and صمحئقتثثثغرهه (مأ ئلئدتسة 0MPI.C Ri is 0CF3, Rs is H and R3 is CH, for use in 1. inhibition of dengue virus replication in a biological sample or patient.
7. Compound for use according to claim 6, further comprising the co-administration of an additional therapeutic agent.
8. Compound for use according to claim 7, said additional therapeutic agent being another antiviral agent.